ProPresent® Antigen Presentation Assay

Hinterberger, M., et al. (2023). “Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.” Sci Rep 13, 5162 (2023). https://doi.org/10.1038/s41598-023-32060-2

Simhadri, V.L., et al. (2021). “Cas9-derived peptides presented by MHC Class II that elicit proliferation of CD4+ T-cells.” Nat Commun 12, 5090 (2021). https://doi.org/10.1038/s41467-021-25414-9

Muraki Y., et al. (2021). “The evaluation of lymph node cell proliferation response by liposomes loaded with major histocompatibility complex class II binding aquaporin 4 antigen peptide.” Bioscience, Biotechnology, and Biochemistry, Volume 85, Issue 3, March 2021, Pages 537–544. https://doi.org/10.1093/bbb/zbaa084

Jankowski W, et al. (2019). “Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.” Blood Adv. 2019 May 14;3(9):1429-1440. https://doi.org/10.1182/bloodadvances.2018030452

Gouw JW, et al. (2018). “Identification of peptides with tolerogenic potential in a hydrolysed whey-based infant formula.” Clin Exp Allergy. 2018 Oct;48(10):1345-1353. https://doi.org/10.1111/cea.13223

Lamberth K., et al. (2017). “Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools.” Sci Transl Med. 2017 Jan 11;9(372):eaag1286. https://doi.org/10.1126/scitranslmed.aag1286

Leone DA, et al. (2017). “Surface LAMP-2 Is an Endocytic Receptor That Diverts Antigen Internalized by Human Dendritic Cells into Highly Immunogenic Exosomes.” J Immunol. 2017 Jul 15;199(2):531-546. https://doi.org/10.4049/jimmunol.1601263

Geletneky K, et al. (2017). “Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.” Mol Ther. 2017 Dec 6;25(12):2620-2634. https://doi.org/10.1016/j.ymthe.2017.08.016

Maraskovsky E., et al. (2016). “Profiling and Comparing the Immunogenicity of a Novel Single-Chain FVIII Molecule (rVIII-SingleChain) for the Treatment of Hemophilia a.” Blood 2016; 128 (22): 4960. https://doi.org/10.1182/blood.V128.22.4960.4960

Xue L, et al. (2016). “Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.” Clin Exp Immunol. 2016 Jan;183(1):102-13. https://doi.org/10.1111/cei.12711

Hock MB, et al. (2015). “Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.” AAPS J. 2015 Jan;17(1):35-43. https://doi.org/10.1208/s12248-014-9684-6

Hui DJ, et al. (2015). “AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes.” Mol Ther Methods Clin Dev. 2015 Sep 30;2:15029. https://doi.org/10.1038/mtm.2015.29

Ventura C, et al. (2012). “HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals.” J Clin Immunol. 2012 Dec;32(6):1305-16. https://doi.org/10.1007/s10875-012-9732-x